Human growth hormone (hGH) is normally produced by acidophilic cells of the anterior lobe of the pituitary gland. Recombinant DNA technology has made it possible to produce rhGH. There have been reports of immunological reactions in patients treated with rhGH. For this reason, it is necessary to check sera of patients for presence of antibody against rhGH. Forty-seven children were treated for up to 6 months with recombinant human growth hormone (rhGH-Novo), 0.1 IV/Kg body weight, subcutaneously, three times weekly. The magnitude of growth response was similar to those expected from clinical experience with pituitary growth hormone. We examined sera for specific antibodies against rhGH by ELISA methods. Four patients developed serum antibodies against growth hormone. The analysis of these four sera by Dot blotting method also showed presence of antibodies against rhGH. In the sera of treated patients, pre-incubated with different concentration of rhGH, specific antibodies were detected by neutralizing assay. This finding was confirmed by ELISA technique. In conclusion, the main concern with anti-GH antibodies could be their ability to neutralize circulating growth hormone and inhibition its growth promoting effect.
Human pituitary growth hormone has been the preferred treatment for growth retardation since its efficacy was first reported 40 years ago (1) . This treatment was discontinued in most countries in 1985 following the deaths from Creutzfeldt-Jakob disease of four patients who received pituitary growth hormone during 1965 and 1975 (2) . Recombinant DNA technology led initially to the synthesis of methionyl-growth hormone (Somatrem) (3 ), which was introduced for clinical use in 1981(4).
Subsequently, Somatropin was introduced with amino-acid chain identical to the human growth hormone. The development of antibodies against growth hormone has been reported in some patients treated with pituitary growth hormone preparations and with earlier preparations of recombinant growth hormone (5) (6) . The concomitant presence of Escherichia-coli polypeptide antibodies in the blood of rhGH-treated patients suggested that antigenicity might be related to the impurity of the preparations (7) (8) .
However, more recent preparations display little antigenecity. The immunogenecity of commercially available rhGH is, therefore, a matter of great concern. The adjuvant effects of unrelated contaminants associated with hGH by disulfide, ionic and / or hydrophobic links, as well as the changes in the intrinsic primary and secondary human growth hormone structure may occur during the production and/or extraction of the hormone and lead to potential immunogenecity (9) (10) . The main concern with anti-GH antibodies is their ability to neutralize circulating growth hormone and its inhibiting growth-promoting effect (9) . Such an effect has been reported in only a few patients presenting extremely high concentrations of antibodies with high binding capacities (11). The long-term significance of any persistent circulating free and complexed growth hormone antibody remains unknown. This study was conducted to search for the immunogenic effect of rhGH presently available in Iran and to provide a measure for evaluation of short-term treatment of patients. Hence, we developed a highly sensitive enzymatic immunological assay to determine the presence and specific binding of antibody against recombinant human growth hormone.
MATERIAL AND METHODS
Peripheral blood was obtained from 41 healthy individuals and 47 children, treated with recombinant human growth hormone, (Somatropin, Novo). All patients were given weekly rhGH doses of 0.1 IU/Kg, three times per week for more than 6 months.
Blood was withdrawn into plastic tubes and centrifuged at 2000 rpm, and the sera were transferred to polypropylene tubes, and stored at _20 0 C before assays.
Children who took part for this study were GH deficient as defined by conventional clinical and biochemical criteria (12). All patients attended the growth clinic at the Children's Hospi tal Medical Center, Tehran. The antisera aided in the optimization of the ELISA assay were also used to detect rhGH anti-IgG antibodies and served as a positive control for the assays, the antisera produced against somatropin (Novo) was used as positive control in the anti-somatropin ELISA assay.
Antibody assay by ELISA
For evaluating antibodies against recombinant GH, 96-well microtiter plates were coated with 100 J.1l per well of growth hormone (0/5J.1g/ml, Novo) in sodium carbonate buffer, pH 9.5 and incubated at room temperature overnight. The plates were then blocked with phosphate-buffered saline, pH 7.0 (PBS), containing 0.5% bovine serum albumin for at least 30 min at room temperature. Serum samples were diluted 1/100 in PBS containing 0.5% tween 20, and 0.01 % Merthiolate and then 100 J.1l of the samples was added to microtiter wells in duplicates and incubated for two hours at 37 0 C. After washing three times with PBS containing 0.05% tween 20, followed by a 100J.11 HRP-labeled rabbit anti -human immunoglobulin antibodies (Dako, Denmark) and tetra methyl benzedine (TMB, Sigma) substrate was added to each well. The reaction was terminated with 1/N sulfuric acid and the absorbance was determined at 450nm in ELISA system (Biotech, USA) (13) .
Neutralization assay
Four patients' sera with high titer of specific antibodies against rhGH were tested by Dot blotting assay. To rule out results due to high titration of nonspecific binding, we conducted a neutralization assay by pre-incubation of patients' sera with different concentrations of recombinant human growth hormone (0-1OOJ.1g/ml) (Novo, Nordisk, Denmark) before ELISA test. Antibody assay after pre-incubation of patients' sera with rhGH was performed as described in antibody assay by ELISA method. In this method increasing concentrations of rhGH led to decreasing optical density cor» of ELISA test.
Dot blotting
Four patients sera with high titer of antibodies against rhGH previously determined by ELISA method were also tested by Dot blotting assay. The recombinant human growth hormone (NOVO) blotted on polyvinylidion difloride (PVDF) membrane and dried skimmed milk were used for blocking the membrane. After one hour incubation of the membranes, they were washed three times with PBS, Tween 20. Then, patients' sera were added (diluted 1/100) to the membranes for two hours in room temperature. The membranes were washed again and HRP-Iabeled goat anti-human IgG was added and they were left for two hour at room temperature.
The membranes were washed and the solution of the substrate (4-Chloro-l-naphtol, H202) was added on each membrane. Finally, they were washed to remove the excess Substrate. The color change, an indication of positive reaction, was read visually.
Statistical analysis
The nonparametric Wilcox on-Mann Whitney twotailed tests were used to compare test values related to control and experimental groups.
RESULTS
In this study, we employed ELISA assay to detect anti rhGH, which is highly sensitive and can detect antibody as low as ng/ml (13) . Due to the relatively high background absorbance associated with assaying serum, it was necessary to dilute the samples. The assay performed locally in laboratory of National Research Center for Genetic Engineering & Biotechnology. The results, presented in Fig. 2 , indicate four out of 47 patients with at least six months of treatment developed anti-hGH antibodies. Fig. I shows mean of antibody titration of patients, which they had developed high titer of anti-hGH antibodies in comparison to healthy individuals. Eight patients developed antibody against hGH with moderate antibody titer. The results showed only four out of 47 patients to have raised high GH antibody binding, which was produced during the 6 months of treatment. The pattern of GH binding for these four patients was similar, exhibiting higher serum antibody levels comparing to other thirty three patients (Fig. 2) . Antibody levels in the sera of patients and healthy individuals indicated that there were not statistically significant differences between sera from low and moderate antibody production group and those from healthy individuals. However, antibody level in the sera of patients with high titer was significantly higher (p<0.046) than that of the healthy control groups (tab.I),
To rule out nonspecific binding, we conducted a neutralization assay by pre-incubation of the four patients' sera with different concentrations of recombinant human growth hormone (Novo, Nordisk, Denmark) before ELISA test. As figure  (3) shows, increasing concentrations of rhGH (0-100 u.g/rnl) led to decreasing optical density in the ELISA system. These results confirm the specificity of four antibodies against recombinant human growth hormone. We also performed Dot blotting of these four patients' sera with high titer of antibodies. Figure 4 shows Dot blotting of blotted rhGH on Polyvinyllidion difloride (PVDF) membrane. Blots one and two (B 1 and B2) show positive reaction (dark color) of patients' sera with high titer antibodies in ELISA methods.
Blots three and four (B3 and B4) show negative reaction with sera of control group. Dot blot assay in this study was employed as confirmatory test.
DISCUSSION
Application of recombinant DNA technology has made the production of unlimited supplies of proteins possible, including human growth hormone that has important therapeutic uses (4, 14) . One of the parameters of interest in the toxicological evaluation of these high molecular weight compounds has been their potential to induce antibody responses in patients. This was considered to be clinically important for several reasons.
First, many years of experience with protein hormones obtained from tissue extracts have shown that antibodies were readily produced in a large number of patients (7, 15) .
This occurred when the protein was of animal origin. For example, insulin from porcine or bovine sources, or even human origin. The use of early preparations of Pit-hGH, with a large amount of contaminating proteins and hGH aggregates, often resulted in the induction of growth inhibiting anti-hGH antibodies (16-18).
Roos's method ofhGH preparation, purification and removing aggregates reduced the antigenicity and the incidence of antibody formation (19) . Surprisingly, the first biosynthetic hGH analogue (met-hGH) from E.Coli was found to be antigenic with a high rate of anti-hGH antibody formation (5) (6) (7) . There have also been reports on the antibody formation against peptides of the host E. Coli (E. Coli polypeptides, ECP), which contaminated the met-hGH in the ngr-range. For this reason, it is important to examined the patients' sera for antibodies, which could possibly be induced by the hormone itselfand/or by contaminating proteins of the host cells. Although there was no evidence ofthe formation of antibodies against human growth hormone, it constituted an increased health risk and thus was judged to be clinically irrelevant in most patients. A low percentage of patients developed antibodies that blocked the therapeutic effectiveness of the hormone (20-21). Second, there was a theoretical concern that antibodies induced by treatment may have an effect on the production of activity of the endogenous hormone, thereby initiating a transient or sustained autoimmune reaction. For many children with hGH deficiency, several years of hGH injections, given 3 times/week, are needed to assure optimum hight. The major objection to the administration of hGH has been the potential for increased immunogenecity (9, 22) .
This study has shown the development of antibodies against rhGH, a feature common to treatment with biosynthetic GH. Serum antibodies in four patients whose sera with high titer was found to react to growth hormone, had the highest binding reactivity by different immunological methods. The incidence of antibody production in patients under pituitary GH treatment amounted to less than 10% to 60% of patients, and seemed to be related to the extraction procedures and purity of the preparation.
Thus, the incidence of antibodies to somatropin is comparable to that associated with less immunogenic pituitary GH preparations. Growth retardation occurred in the presence of such antibodies in about 5% of the patients (23) (24) (25) (26) . Ourresults has shown 8.5%of the patients developed antibodies against rhGH. The mechanisms responsible for the induction of GH antibodies in response to GH treatment remained undefined.
In conclusion, the main concern with anti-GH antibodies could be their ability to neutralize circulating growth hormone and to inhibit its growth promoting effect.
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